Interim results from a phase 3 Ebola vaccine study in Guinea

The Lancet

Volumn 386, Issue 9996, 2015, Pages 831-833

  Krause, Philip R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

EBOLA HEMORRHAGIC FEVER; EPIDEMIC; GUINEA; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; MORBIDITY; PRIORITY JOURNAL; SHORT SURVEY; VACCINE FAILURE; FEMALE; HEMORRHAGIC FEVER, EBOLA; MALE;

EBOLA VACCINES; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE;

EID: 84940908674     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)00002-1     Document Type: Note

References (4)

1. AM Henao-Restrepo, IM Longini, M Egger et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial Lancet 386 2015 857 866
2. Ebola ça Suffit Ring Vaccination Trial Consortium The ring vaccination trial: a novel cluster randomized controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola BMJ 351 2015 h3740
3. S Berkley Ebola vaccine: the need to act now The New York Times Aug 2, 2015 http://www.nytimes.com/2015/08/03/opinion/ebola-vaccine-the-need-to-act-now.html (accessed Aug 2, 2015).
4. World Health Organization Ebola situation reports http://apps.who.int/ebola/current-situation/ebola-situation-report-19-august-2015 Aug 19, 2015 (accessed Aug 19, 2015).